LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...

Nov 9 (Reuters) - An AstraZeneca (AZN.L), opens new tab executive said he felt encouraged by "incredibly promising" COVID-19 vaccine trial data unveiled by Pfizer and its German partner BioNTech, ...

The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular franchises. For example, sales of Tagrisso, an EGFR inhibitor for the ...

Amid looming 100% tariffs on imported drugs by the Trump administration, global pharmaceutical companies are significantly ...

Pharmaceutical giant Pfizer has been circling its smaller rival for months. AstraZeneca has rejected every offer saying Pfizer undervalues the... Pfizer Drops $119 Billion Bid For AstraZeneca It would ...

PFE's oncology results should reflect steady growth from Seagen ADCs and key brands, offset by pricing and competitive ...